Table 1. Summary of participant demographics.
| COVID-19 primed group | Non-COVID-19 primed group | |
|---|---|---|
| (n = 114) | (n = 86) | |
| Mean age (SD1) | 54.0 (12.3) | 54.2 (12.3) |
| Gender (Male) | 68/114 (59.6%) | 50/86 (58.1%) |
| Race: | ||
| White | 84/114 (73.7%) | 63/86 (73.2%) |
| South Asian | 24/114 (21.0%) | 20/86 (23.2%) |
| African-Caribbean | 6/114 (5.3%) | 3/86 (3.5%) |
| Time on dialysis prior to transplant (IQR2) | 31 (2–70) months | 29 (2–71) months |
| Diabetes: | ||
| Pre-transplant | 13/114 (11.4%) | 10/86 (11.6%) |
| PTDM 3 | 17/114 (14.9%) | 14/86 (16.3%) |
| Live Donor Transplant Recipient | 20/114 (17.5%) | 17/86 (19.8%) |
| Time Post Transplant (IQR) | 52 (22–122) months | 51 (20–123) months |
| Prior Acute Rejection4 | 17/114 (14.9%) | 15/86 (17.4%) |
| Last eGFR5 prior to shielding (SD) | 45 (18) ml/min | 46 (17) ml/min |
| Tacrolimus versus non-Tacrolimus based immunosuppression6 | 85/114 (74.6%) | 67/86 (77.9%) |
| Body Mass Index (SD) | 27.9 (5.6) kg/m2 | 28.2 (5.7) kg/m2 |
1: Standard Deviation (parametric data)
2: Interquartile range (non-parametric data)
3: Post Transplant Diabetes Mellitus
4: Acute transplant rejection was diagnosed by transplant biopsy in all cases; any episode at any time post-transplant (irrespective of histological or clinical classification) was captured
5: Estimated Glomerular Filtration Rate
6: Most ‘non-Tacrolimus’ treated patients received ciclosporin. A minority of patients were treated with either sirolimus or no calcineurin inhibitor at all (total n = 6 across both arms of study)